Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | PIM1 | P11309 | 3/20 | 0.40 |
| ▸ | PRKACA | P17612 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30156323 | 1.00 | GSK3B (0.47) | GSK3BFLT3PSEN1PSEN2APH1B | |
| SCHEMBL25084623 | 0.92 | TGFBR1 (0.43) | GSK3BFLT3PSEN1PSEN2APH1B | |
| SCHEMBL30156175 | 0.92 | TGFBR1 (0.43) | GSK3BFLT3PSEN1PSEN2APH1B | |
| SCHEMBL30156228 | 0.88 | TGFBR1 (0.36) | GSK3BFLT3PSEN1PSEN2APH1B | |
| SCHEMBL25084789 | 0.88 | TGFBR1 (0.36) | GSK3BFLT3PSEN1PSEN2APH1B | |
| SCHEMBL25084624 | 0.86 | TGFBR1 (0.36) | FLT3TGFBR1KDRFGFR1 | |
| SCHEMBL30155987 | 0.86 | TGFBR1 (0.36) | FLT3TGFBR1KDRFGFR1 | |
| SCHEMBL25084487 | 0.85 | MIF (0.39) | FLT3TGFBR1CDC7EGLN1 | |
| SCHEMBL30155883 | 0.85 | MIF (0.39) | FLT3TGFBR1CDC7EGLN1 | |
| SCHEMBL25084675 | 0.85 | TGFBR1 (0.39) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | GSK3B 624/4885FLT3 143/4885PSEN1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.